Targeting Innovation

Diasome is developing hepatocyte directed vesicle (HDV) technology to reduce the incidence of high and low blood sugar levels in people with diabetes to improve disease management and quality of life.
HDV technology is being developed as an additive to all forms of insulin to improve its safety and efficacy by restoring the liver’s natural role in blood glucose control.

Location matters

To achieve optimal outcomes, insulin therapy needs to address all three key components of insulin therapy: dosage, timing, and location.

Latest updates

View our press releases and follow our journey.

Stay up-to-date with Diasome.

Enter your email address
Oops! Something went wrong while submitting the form.
10000 Cedar Avenue
Suite 6
Cleveland, OH 44106
+1.216.444.7110
info@diasome.com

Media Relations

Cherilyn Cecchini, M.D.
LifeSci Public Relations
+1.646.876.7110
ccecchini@lifescipublicrelations.com